SavedAdd your journal

Journals / Türk Nöroşirürji Dergsi / 2018 / Cilt: 28 - Sayı: 3

Brain Tumor Stem Cell

Beyin Tümörü Kök Hücresi

Meliha GÜNDAĞ PAPAKER
Güven ÇETİN
Mehmet Hakan SEYITHANOĞLU
Erdinç ÖZEK
Serkan KITIŞ
Tolga Turan DÜNDAR
Anas ABDALLAH
Pages
360–365
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review presents a summary of the present knowledge on GBMSC and the developing current treatment options with GBMSC-related mechanisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glioblastoma multiforme (GBM) is an aggressive, malignant, and lethal brain tumor, resistant to all current forms of treatment.
📊
Key Findings & Data:Despite all the treatment options, the median survival is less than 15 months.
💡
Conclusion & Impact:This review presents a summary of the present knowledge on GBMSC and the developing current treatment options with GBMSC-related mechanisms.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glioblastoma multiforme (GBM) is an aggressive, malignant, and lethal brain tumor, resistant to all current forms of treatment. Despite all the treatment options, the median survival is less than 15 months. More effective targeted therapeutic regimens are therefore required. Glioblastoma multiforme Stem Cell (GBMSC) or Cancer stem cells (CSCs) determine the heterogenic biology and resistance to both radio- and chemotherapy, the aggressiveness and the treatment failure of these lesions. This review presents a summary of the present knowledge on GBMSC and the developing current treatment options with GBMSC-related mechanisms.

Özet

Glioblastoma multiforme (GBM), tedavi direnci olan agresif seyirli malign beyin tümörüdür. Cerrahi rezeksiyon, radyoterapi vekemoterapi standart tedavisidir. Tüm etkin tedavi kombinasyonlarına rağmen ortalama sağ kalım süresi 15 aydan azdır. Bundandolayı daha etkin tedavi hedefleri gereklidir. Glioblastoma multiforme kök hücresi (GBMKH)veya kanser kök hücresi (KKH) veya beyintümörü kök hücresi (BTKH), hem radyoterapi hem kemoterapi direncinden, tümör rekürrensinden ve tümörün heterojen yapısındansorumlu tutulmaktadır. Yakın gelecekte tümör kök hücrelerine ait, genetik, epigenetik ve moleküler faktörler, mikroçevresel ortam vebunlara karşı immün sistem yanıtı beyin tümörleri tedavi çalışmalarının büyük bölümünü oluşturacaktır. Bu derlemede beyin tümörükök hücresi hakkında güncel bilgileri ve yeni tedavi seçeneklerini sunmayı amaçladık.

🔖

Cite This Article

PAPAKER, M. G., ÇETİN, G., SEYITHANOĞLU, M. H., ÖZEK, E., KITIŞ, S., DÜNDAR, T. T., ABDALLAH, A. (2022). Brain Tumor Stem Cell. Türk Nöroşirürji Dergsi, Cilt: 28 - Sayı: 3, 360–365. https://ajindex.com/articles/655105

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Abou-Antoun TJ, Hale JS, Lathia JD, Dombrowski SM: Brain cancer stem cells in adults and children: Cell biology and therapeutic implications. Neurotherapeutics 14:372–384, 2017
  2. Aguirre A, Rubio ME, Gallo V: Notch and EGFR pathway interaction regulates neural stem cell number and self- renewal. Nature 467:323-327, 2010 Altaner C: Glioma cancer stem cells and their role in therapy. Atlas Genet Cytogenet Oncol Haematol 16(10):757 -764, 2012
  3. Altaner C, Altanerova V: Stem cell based glioblastoma gene therapy. Neoplasma 59(6):756-760, 2012
  4. Dimov I, Tasić-Dimov D, Conić I, Stefanovic V: Glioblastoma multiforme stem cells. Scientific World Journal 11:930-958, 2011 Ekenel M: Beyin tümörlerinde hedefe yönelik tedaviler. Türk Nöroşir Derg 27(2):218-222, 2017 7. Facchino S, Abdouh A, Bernier G: Brain cancer stem cells: Current status on glioblastoma multiforme. Cancers (Basel) 3(2):1777-1797, 2011
  5. Gardeck AM, Sheehan J, Low WC: Immune and viral therapies for malignant primary brain tumors. Expert Opin Biol Ther 17(4):457-474, 2017
  6. Glaser T, Han I, Wu L, Zeng X: Targeted nanotechnology in glioblastoma multiforme. Frontiers in Pharmacology 8:166- 180, 2017
  7. Hofstetter CP, Burkhardt JK, Shin BJ, Gürsel DB, Mubita L, Gorrepati R, Brennan C, Holland EC, Boockvar JA: Protein phosphatase 2A mediates dormancy of glioblastoma multifor me-derived tumor stem-like cells during hypoxia. PLoS One 7(1): 257-263, 2012
  8. Imayoshi I, Sakamoto M, Yamaguchi M: Essential roles of Notch signaling in maintenance of neural stem cells in developing and adult brains. J Neurosci 30:3489-3498, 2010
  9. Iwadate Y, Matsutani T, Hirono S, Shinozaki N, Saeki N: Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma. J Neurooncol 129:101-107, 2016
  10. Kriegstein A, Alvarez-Buylla A: The glial nature of embryonic and adult neural stem cells. Annu Rev Neurosci 32:149-184, 2009
  11. Louis DN, Perry A, Reifenberger G, Deimling AV, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler OT, Kleihues P, Ellison DW: The 2016 World Health Organization Classification of Tumours of the Central Nervous System: A summary: Acta Neuropathol 131(6):803-820, 2016
  12. MineoM, Ricklefs F, Rooj AK: The long non-coding RNA HIF1A-AS2 facilitates the maintenance of mesenchymal glioblastoma stem-like cells in hypoxic niches. Cell Rep 15:2500-2509, 2016 Özyurt ME: Düşük dereceli gliomalar ve tedavileri. İçinde: Kaynar MY, Dündar TT (ed), Beyin Tümörleri Kök Hücresi ve Tümerogenezisi, cilt 1,